| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Combined evaluation of biomarkers as predictor of maintained remission in Crohn’s disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Elisa Sollelis, Régine Minet-Qunard, Guillaume Bouguen, Marion Goutte, Felix Goutorbe, Damien Bouvier, Bruno Pereira, Gilles Bommelaer and Anthony Buisson |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Anthony Buisson, MD, PhD, Associate Professor, Senior Lecturer, Gastroenterology Department, University Hospital Estaing, 1 place Aubrac, Clermont-Ferrand F-63100, France. a_buisson@hotmail.fr |
| Key Words |
Anti-tumor necrosis factor; Tight control; C-reactive protein; Crohn’s disease activity index; Faecal calprotectin; Crohn’s disease; Biomarkers |
| Core Tip |
The CALM trial reported that a tight control of inflammation achieved better outcomes than conventional monitoring, but did not explore specifically the value of each biomarker. In this multicentre study, we investigated the performances of Crohn’s disease (CD) activity index (CDAI), C-reactive protein (CRP) and faecal calprotectin (Fcal) variation, alone or combined, after 12 wk of anti-tumor necrosis factor (TNF) therapy to predict corticosteroids-free remission (CFREM) at one year, in CD patients treated with anti-TNF. We showed the complementarity of the variation of CDAI, CRP and Fcal after anti-TNF induction therapy, to predict CFREM at one year, and confirmed that Fcal was the most effective predictor among these three markers. |
| Publish Date |
2019-05-20 09:05 |
| Citation |
Sollelis E, Quinard RM, Bouguen G, Goutte M, Goutorbe F, Bouvier D, Pereira B, Bommelaer G, Buisson A. Combined evaluation of biomarkers as predictor of maintained remission in Crohn’s disease. World J Gastroenterol 2019; 25(19): 2354-2364 |
| URL |
https://www.wjgnet.com/1007-9327/full/v25/i19/2354.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v25.i19.2354 |
